The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
The pharmacology of statins
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial
Huijgen, R., Boekholdt, S. M., Arsenault, B. J., Bao, W., Davaine, J., Tabet, F., Petrides, F., Rye, K., DeMicco, D. A., Barter, P. J., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.043 · Cited by 56
RetractedOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Takemoto, M., & Liao, J. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1101.098486 · Cited by 1,272
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.
ENDO, A., KURODA, M., & TSUJITA, Y. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.1346 · Cited by 954
Cited by
Pleiotropic Effects of Statins on the Cardiovascular System
Oesterle, A., Laufs, U., & Liao, J. K. (2017) · Circulation Research · doi:10.1161/circresaha.116.308537 · Cited by 1,247
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 407
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy182 · Cited by 370
Gender differences in the effects of cardiovascular drugs
Tamargo, J., Rosano, G., Walther, T., Duarte, J., Niessner, A., Kaski, J., Ceconi, C., Drexel, H., Kjeldsen, K., Savarese, G., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw042 · Cited by 317
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Molecular Pathways Underlying Cholesterol Homeostasis
Afonso, M. S., Machado, R. M., Lavrador, M., Quintao, E. C. R., Moore, K., & Lottenberg, A. (2018) · Nutrients · doi:10.3390/nu10060760 · Cited by 138
Statins and the Brain: More than Lipid Lowering Agents?
Fracassi, A., Marangoni, M., Rosso, P., Pallottini, V., Fioramonti, M., Siteni, S., & Segatto, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170703101816 · Cited by 116
HDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114
Tavakkoli, A., Johnston, T. P., & Sahebkar, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107483 · Cited by 73
Lipid Lowering Drugs: Present Status and Future Developments
Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73
Self-citationScreening for YAP inhibitors identifies statins as modulators of fibrosis
Santos, D. M., Pantano, L., Pronzati, G., Grasberger, P., Probst, C. K., Black, K. E., Spinney, J. J., Hariri, L. P., Nichols, R., Lin, Y., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0296oc · Cited by 72
Advances in treatment of Dyslipidemia
Dybiec, J., Baran, W., Dąbek, B., Fularski, P., Młynarska, E., Radzioch, E., Rysz, J., & Franczyk, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713288 · Cited by 55
Marcheggiani, F., Cirilli, I., Orlando, P., Silvestri, S., Vogelsang, A., Knott, A., Blatt, T., Weise, J. M., & Tiano, L. (2019) · Aging · doi:10.18632/aging.101926 · Cited by 53
Evidence-based review of statin use in patients with HIV on antiretroviral therapy
Chastain, D. B., Stover, K. R., & Riche, D. M. (2017) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2017.01.004 · Cited by 54
Application of nanotechnology to improve the therapeutic benefits of statins
Korani, S., Korani, M., Bahrami, S., Johnston, T. P., Butler, A. E., Banach, M., & Sahebkar, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.023 · Cited by 51
Statins: Neurobiological underpinnings and mechanisms in mood disorders
Walker, A. J., Kim, Y., Borissiouk, I., Rehder, R., Dodd, S., Morris, G., Nierenberg, A. A., Maes, M., Fernandes, B. S., Dean, O. M., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.012 · Cited by 33
Dohlmann, T. L., Kuhlman, A. B., Morville, T., Dahl, M., Asping, M., Orlando, P., Silvestri, S., Tiano, L., Helge, J. W., Dela, F., et al. (2022) · Antioxidants · doi:10.3390/antiox11091698 · Cited by 31
Repurposing of atorvastatin emulsomes as a topical antifungal agent
Eita, A. S., M. A. Makky, A., Anter, A., & Khalil, I. A. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2149898 · Cited by 24
“Statins are a recognized group of drugs that are primarily used as plasma cholesterol-lowering agents upon inhibiting the hydroxy-methyl-glutaryl-CoA (HMG-CoA) reductase enzyme (Sirtori, 2014).”
BackgroundAn Updated Review and Meta Analysis of Lipoprotein Glomerulopathy
Li, M.-S., Li, Y., Liu, Y., Zhou, X.-J., & Zhang, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.905007 · Cited by 25
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Tramontano, D., Bini, S., Maiorca, C., Di Costanzo, A., Carosi, M., Castellese, J., Arizaj, I., Commodari, D., Covino, S., Sansone, G., et al. (2025) · Drugs · doi:10.1007/s40265-025-02158-0 · Cited by 17
Das, D., Peng, X., Lam, A.-T. N., Bader, J. S., & Avramopoulos, D. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.041 · Cited by 17
Lin, Y.-C., Lai, T.-S., Chen, Y.-T., Chou, Y.-H., Chen, Y.-M., Hung, K.-Y., & Tu, Y.-K. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.09.037 · Cited by 10
Metadata
- Authors
- Sirtori, C. R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 88
- Pages
- 3-11
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2039944972
- Cited by
- 691
- References
- 90
- FWCI
- 24.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.